Lodoz Adverse Reactions

Common (≥ 1% and < 10%), uncommon (≥ 0.1% and < 1%), rare (≥ 0.01% and < 0.1%), very rare (< 0.01%) including isolated cases.
Neoplasms benign, malignant and unspecified (including cysts and polyps): Not known: Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma).
Description of Selected Adverse Reactions: Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dose-dependent association between hydrochlorothiazide and NMSC has been observed (see also Precautions and Pharmacology: Pharmacodynamics under Actions).
Blood and lymphatic system disorders: Rare: leucopenia, thrombocytopenia. Very rare: agranulocytosis.
Metabolism and nutrition disorders: Uncommon: loss of appetite, hyperglycaemia, hyperuricaemia, disturbances of fluid and electrolyte balance (in particular hypokalaemia and hyponatraemia, also hypomagnesaemia and hypochloraemia as well as hypercalcaemia). Very rare: metabolic alkalosis.
Psychiatric disorders: Uncommon: depression, sleep disorder. Rare: nightmare, hallucination.
Nervous system disorders: Common: dizziness*, headache*.
Eye disorders: Rare: reduced tear flow (to be taken into consideration in patients wearing contact lenses), visual disturbances. Very rare: conjunctivitis. Not known: choroidal effusion, acute myopia, acute angle-closure glaucoma.
Ear and labyrinth disorders: Rare: hearing disorders.
Cardiac disorders: Uncommon: bradycardia, AV-conduction disturbances, worsening of pre-existing heart failure.
Vascular disorders: Common: feeling of coldness or numbness in extremities. Uncommon: orthostatic hypotension. Rare: syncope.
Respiratory, thoracic and mediastinal disorders: Uncommon: bronchospasm in patients with bronchial asthma or history of obstructive airways disease. Rare: allergic rhinitis. Very rare: acute respiratory distress syndrome (ARDS) (see Precautions).
Gastrointestinal disorders: Common: gastrointestinal complaints such as nausea, vomiting, diarrhoea, constipation. Uncommon: abdominal complaints. Very rare: pancreatitis.
Hepatobilary disorders: Rare: hepatitis, jaundice.
Skin and subcutaneous tissue disorders: Rare: hypersensitivity reactions such as pruritus, flush, rash and angioedema, photodermatitis, purpura, urticaria. Very rare: anaphylactic reactions, toxic epidermic necrolysis (Lyell syndrome), alopecia, cutaneous lupus erythematosus. Beta-blockers may provoke or worsen psoriasis or induce psoriasis-like rash.
Musculoskeletal and connective tissue disorders: Uncommon: muscle weakness, muscle cramps.
Reproductive system and breast disorders: Rare: erectile dysfunction.
General disorders: Common: fatigue*. Uncommon: asthenia. Very rare: chest pain.
Investigations: Uncommon: increase in amylase, reversible increase of serum creatinine and urea, increased triglyceride and cholesterol levels, glucosuria. Rare: increase in liver enzymes (ASAT, ALAT).
*These symptoms occur in particular at the start of treatment. They are generally mild and mostly disappear within 1-2 weeks.